BackAccelerate Diagnostics Overview

Accelerate Diagnostics Current Cash

Latest current cash for AXDX: $15M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$15.10M
24.39% YoYΔ $2.96M vs prior year quarter

Peer average

Loading

Accelerate Diagnostics Current Cash History

Loading

Accelerate Diagnostics vs. peers: Current Cash Comparison

Loading

Accelerate Diagnostics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Accelerate Diagnostics (AXDX) FAQ

Accelerate Diagnostics's current cash stands at $15M as of December 2024. That compares with $12M in the prior-year period — up 24.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Accelerate Diagnostics reported $15M in current cash versus $12M a year earlier — a 24.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $12M in the prior-year period — up 24.4% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Accelerate Diagnostics's current cash evolved across reporting periods, while the comparison chart places AXDX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current cash is commonly used to spot outliers. Accelerate Diagnostics's reading of $15M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.